Cite

HARVARD Citation

    Eriksen, J. et al. (n.d.). OC-0271: 5-Y update of the randomized phase III trial DAHANCA19: Primary (Chemo) RT +/- zalutumumab in HNSCC. Radiotherapy and oncology. pp. S137-S138. [Online]. 
  
Back to record